4//SEC Filing
Goddard Glenn 4
Accession 0001209191-22-015917
CIK 0001652130other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 7:38 PM ET
Size
17.2 KB
Accession
0001209191-22-015917
Insider Transaction Report
Form 4
Goddard Glenn
EVP, Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2022-01-01+3,062→ 3,062 total - Sale
Common Stock
2022-01-01$112.24/sh−1,013$113,699→ 2,049 total - Award
Common Stock
2022-03-01+12,720→ 14,769 total - Exercise/Conversion
Restricted Stock Unit
2022-01-01−3,062→ 9,188 totalFrom: 2022-01-01Exp: 2031-03-02→ Common Stock (3,062 underlying) - Award
Stock Option (right to buy)
2022-03-01+12,720→ 12,720 totalExercise: $79.85Exp: 2032-02-28→ Common Stock (12,720 underlying)
Footnotes (5)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022.
- [F3]Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- [F4]On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
- [F5]This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
Issuer
Intellia Therapeutics, Inc.
CIK 0001652130
Entity typeother
Related Parties
1- filerCIK 0001581992
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 7:38 PM ET
- Size
- 17.2 KB